Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Longitudinal monitoring

Following Sjögren’s over time

Which checks matter, how often they are needed and when the plan should change

Follow-up is more than repeating blood tests. It should help you understand what is stable, what has changed, whether treatment remains useful and safe, and which symptoms need attention before the next appointment. Different parts of your care may need different schedules.

Start with the question that brought you here: when to arrange a check, what a result means or which change should prompt earlier contact. This guide connects the chapters on treatment goals, organ treatment, dryness, fatigue and daily function.

Why do I need follow-up if I feel reasonably well?

Some useful checks detect a problem before it causes obvious symptoms, while others establish that the current plan is working. Monitoring also helps avoid unnecessary treatment when a symptom has a different explanation.

Follow-up addresses four questions:

  • Is Sjögren’s causing active inflammation?
  • Has an organ already been damaged?
  • How are you managing everyday activities?
  • Is treatment causing harm?

The answers can differ. Joint inflammation may be controlled while poor sleep, dryness or pain from joint wear or strain still needs care. Feeling better matters, but it does not answer every question about medication safety.

“Stable” should therefore have a meaning: stable breathing tests, kidney function, joint examination or ability to manage a usual activity. It does not necessarily mean symptom-free or cured. Ask which part of the illness is being followed and which finding would change the plan. That makes follow-up more useful than a general statement that all tests are fine. [R01] [R02]

Back to contents ↑

How often should I be seen?

The interval depends on disease activity, organ involvement, treatment and recent changes. There is no proven single timetable for everyone with Sjögren’s.

European rheumatology recommendations (EULAR) give examples ranging from monthly review for high disease activity to every 6–12 months for low activity. The British Society for Rheumatology (BSR) emphasizes an individual plan because evidence for the best interval is limited.

These examples do not mean that everyone who feels stable can safely wait a year. Starting a medicine, changing a dose or investigating a new abnormality may require earlier checks. [R01] [R02]

Keep separate dates for the disease review, medication-safety blood tests, eye and dental care, and checks of a particular organ. A clinic visit in 6 months does not mean that medication blood tests can wait 6 months.

Before leaving, clarify the next step, who will arrange and review it, and which change should prompt earlier contact. If a test is difficult to access, agree on a workable alternative with the responsible team so it does not quietly disappear from the plan.

Back to contents ↑

What information makes an appointment more useful?

Describe a change with a date and a concrete example. “I now stop halfway up the stairs” is more informative than “everything is worse.” Include what recovery feels like and whether the change is continuous or comes in episodes.

Bring an accurate medication list, including actual doses, supplements, missed periods of treatment and new medicines from other clinicians. Include infections, hospital visits, falls and procedures since the last review. If a gland swelled and then returned to normal, describe the timing, side, pain and fever; a dated photograph may help explain the episode.

Choose the few problems that affect your life most. Note what you could previously do and what now interrupts it. You do not need an exhausting daily diary unless a specific pattern is being investigated. The purpose is to give the clinician a reliable comparison, not to prove that your symptoms are serious enough. Keep copies of important outside reports so that the next decision uses the actual findings rather than a remembered summary.

Optional visit aid: the Sjögren’s Foundation Symptom & Impact Tracker (English) helps organize recent symptoms, their effect on daily life and priorities for your appointment. Complete it before a visit; it is not a diagnostic test or a reason to delay urgent care.

Back to contents ↑

Which blood and urine tests do I need?

Tests should answer a defined question. The right set depends on your previous findings, medicines and symptoms; a longer list is not automatically better.

Test or groupWhat it may help assess
Blood countAnemia, changes in white cells or platelets, and some treatment effects
Kidney function and electrolytesFiltration, potassium and acid balance; these are different functions
Urine testingBlood, protein and other clues to a kidney or urinary problem
Liver testsTreatment safety or a separate liver question
Selected immune, thyroid or other testsA specific disease pattern, risk feature or competing cause of symptoms

BSR recommends several tests at the initial assessment and repeating them when they are needed to answer a clinical question. That does not mean repeating every initial test at every visit.

An abnormal result needs an explanation: medication, infection, dehydration or another illness may contribute. Ask who will review the result and what will happen if it is abnormal. Normal routine blood tests do not rule out every lung, nerve, eye or gland problem. [R01] [R07] [R16]

Back to contents ↑

Should my antibodies be repeated until they become normal?

An antibody can remain positive even when the condition is well controlled. Its continued presence does not automatically mean that treatment has failed or that a new symptom is inflammatory.

ANA, SSA/SSB and anticentromere antibodies are different immune-system tests that help clarify the diagnosis and pattern of disease. They cannot replace an assessment of a newly swollen gland, a kidney problem or breathlessness. Repeating a test can help when the clinical question has changed; ask what decision the result could affect. [R01] [R02] [R15]

Some other immune tests have a different purpose. Complement is a group of immune-system proteins. Cryoglobulins are proteins that can clump together when a blood sample cools. These results, and findings of other abnormal blood proteins, can help assess selected patients. They remain clues to interpret, not a diagnosis of cancer or organ damage on their own.

In some nerve disorders linked to cryoglobulins, repeating these markers is part of a focused plan alongside the neurological examination. Not everyone needs the same tests at the same intervals. Ask how each test relates to your situation. [R05]

Back to contents ↑

What if a salivary gland or lymph node stays enlarged?

A new or changing swelling needs assessment. Sjögren’s can cause it, but so can infection, a blocked salivary duct or another problem. An earlier reassuring scan does not automatically explain a later change.

Describe whether the swelling is on one side, is a distinct lump, comes and goes or remains present. Note pain, any link to meals, fever or another new symptom. A persistent swelling, unexplained lump, unexplained weight loss or drenching night sweats should be assessed directly without waiting months. Painful swelling with fever may need same-day care. [R01]

Lymphoma is one possible concern, not the explanation for every enlarged gland. Some findings change the level of concern, but no single blood test establishes the diagnosis. When tissue is needed, the team chooses the appropriate site and biopsy method. A small lip biopsy used to establish Sjögren’s is not the same as sampling a new lesion in a major salivary gland. [R09]

Back to contents ↑

Would an ultrasound every year make me safer?

An ultrasound is useful when it answers a particular question. Repeating it automatically is not the same as investigating a new lump or a meaningful change.

In one retrospective study, none of 569 screening examinations in asymptomatic patients detected lymphoma, and some generated additional follow-up testing. This does not prove that imaging is never useful without symptoms; the study came from one center. It does challenge the idea that an annual scan for everyone is necessarily better care. [R08]

Ask whether the proposed study is evaluating a palpable lesion, a persistent enlargement, an earlier uncertain result or a specific risk concern. A normal result belongs to that time point; it should not delay assessment of later changes. An abnormal scan also does not automatically mean cancer. If concern remains, further evaluation may include appropriately targeted tissue sampling. Neither repeated scans nor a prior benign biopsy provide a permanent answer to a newly changing problem. [R09]

Back to contents ↑

Do I need regular lung scans if I do not feel short of breath?

Screening for a possible lung problem and following known lung disease are different tasks. Testing without known lung disease is guided by risk and clinical findings, not an automatic CT schedule for everyone.

Report a new cough, breathlessness or difficulty walking your usual distance. Pulmonary function tests measure how the lungs work, including breathing volumes and transfer of gas into the blood. A high-resolution CT gives detailed pictures of lung tissue. These tests answer different questions; a normal chest X-ray does not rule out all important lung changes.

Symptoms may also come from the airways, the heart or an infection, so their cause needs to be established. [R03] [R04]

Interstitial lung disease (ILD) affects the tissue around the lungs’ tiny air sacs. For diagnosed Sjögren’s-related ILD, ERS/EULAR guidance suggests pulmonary function tests every 3–6 months during the first year and at least every 6–12 months afterward, or earlier if worsening is suspected. ACR/CHEST guidance allows a wider interval during the first year. Evidence for the exact timing is limited.

These schedules do not automatically apply to someone without ILD. Your plan should identify which test will be compared over time and what a repeat CT is expected to clarify or change. [R03] [R04]

Back to contents ↑

Can my kidneys need attention even if creatinine looks familiar?

Kidneys filter blood, but they also regulate salts and acid balance. A familiar creatinine result does not describe all those functions.

Depending on the question, checks may include potassium, bicarbonate (which helps assess acid balance), urine and urine protein, as well as creatinine and eGFR, an estimate of how well the kidneys filter blood. Sjögren’s can affect the kidney tubules, the tiny tubes that help regulate salts and acids; other kidney problems need a different evaluation. A normal result in one part of the assessment does not cancel out an abnormal result in another. [R01] [R16]

Report new swelling, changes in urination, marked weakness or palpitations. Severe weakness or a serious electrolyte disturbance can need urgent care. Do not try to correct a suspected potassium shortage yourself: both too little and too much potassium can be dangerous.

If you have established kidney disease, agree which clinician will follow the results and when tests are due. A change could relate to Sjögren’s, dehydration, a medicine, infection or another cause. The next decision depends on the explanation.

Back to contents ↑

How should numbness, burning pain or balance problems be followed?

Changes in strength, sensation, balance and function matter alongside the pain level. Less burning pain does not always mean that nerve injury has stopped.

Describe where the symptoms began, whether both sides are affected, whether the area is spreading, and any new falls, weakness or difficulty using your hands. Nerve problems have different types and causes. Electrical nerve tests assess how some nerves carry signals. A normal result does not rule out a problem with small nerve fibers, which carry pain and temperature signals and may need other tests. The choice follows the suspected problem, not one test calendar for everyone. [R05]

A useful plan names the abilities and examination findings to compare over time. New, rapidly increasing weakness, difficulty lifting the front of the foot (foot drop) or a clear change in walking needs early assessment. Sudden weakness, speech difficulty or another abrupt loss of a specific ability needs emergency care.

A diagnosis of chronic neuropathy, meaning a long-standing nerve problem, should not automatically explain every new symptom pattern. Even stable symptoms may need rehabilitation and pain treatment when stronger immune treatment is not the answer.

Back to contents ↑

Do I still need eye and dental care when inflammation is controlled?

Yes. The glands may still produce too few tears or too little saliva. Local prevention remains important: controlling inflammation elsewhere does not automatically protect the cornea, the clear front surface of the eye, or prevent new cavities.

Eye follow-up considers the surface of the eye, corneal findings, symptoms and response to treatment. Tell your eye-care team about symptoms that are new, worsening or not improving with treatment. New eye pain with light sensitivity or reduced vision needs urgent eye assessment. Retinal screening for hydroxychloroquine is a separate task; a routine dryness visit may not include it. [R01] [R17]

Dental follow-up depends on cavity risk, saliva production and the current state of your teeth. Fluoride and other preventive measures remain important even when your mouth feels more comfortable. If new cavities keep appearing, prevention needs reassessment, as well as cleaning.

The dental team should set the next review interval. Ask what has changed and which step should reduce further damage. Mouth comfort and tooth protection are related, but they are different outcomes. [R10]

Back to contents ↑

Why are blood tests needed when a medicine has not changed?

Your kidney function, other medicines or general health may change even when the prescription stays the same. Safety monitoring can therefore remain necessary after treatment has become familiar.

Some medicines require checks of blood counts, liver tests and kidney function. The frequency depends on the specific drug and your risk. Testing is often closer together after starting or changing treatment, then adjusted once the situation is stable. A low-risk schedule from a guideline is not a personal instruction to delay or skip tests. [R07]

Know who orders the tests and who acts on the results. If several clinicians prescribe medicines, keep one accurate list and report new prescriptions and supplements. Normal safety tests do not prove that a medicine is working; an abnormal result does not always identify its cause.

If nausea, infections or another problem lead you to interrupt treatment, tell the prescriber. Your record should show what you actually take so that you can agree on a safer plan you can follow.

Back to contents ↑

What eye checks do I need while taking hydroxychloroquine?

The retina is the light-sensitive layer at the back of the eye. Hydroxychloroquine screening looks for early damage there, before you notice a change in vision. This is different from a dry-eye examination or a glasses check.

The American Academy of Ophthalmology (AAO) 2025 revision advises a baseline examination soon after treatment starts. It includes a view of the back of the eye, optical coherence tomography (OCT), which shows detailed layers of the retina, and fundus autofluorescence (FAF), a special image that helps reveal changes in tissue at the back of the eye.

Annual retinal screening with OCT and FAF is recommended during treatment. It may be deferred during the first 5 years if there are no significant risk factors. Your eye specialist should record whether that exception applies to you and when your next screening is due. [R06]

Risk depends on dose, duration, kidney disease, other medicines such as tamoxifen, and age when treatment began. Report changes in kidney function and bring an accurate treatment history. Feeling that your vision is normal does not replace screening.

If a finding is uncertain or concerning, the eye specialist and prescriber should coordinate any confirmation needed and the treatment decision. An unclear test does not by itself settle whether to continue or stop the medicine. Agree on the next step rather than stopping it permanently on your own.

Back to contents ↑

What should be reviewed about infections and vaccines?

The infection-prevention plan may change when medicines affecting the immune system change. Testing before a particular drug or after a new exposure is different from repeating every infection test at every visit. [R12]

Vaccine timing can matter, especially with medicines such as rituximab that reduce B cells, a type of immune cell. Live and non-live vaccines need different plans; the timing of a flu vaccine may also differ from other vaccines. Match the current age- and risk-based vaccine schedule to your treatment. Ask for a specific plan rather than stopping medicines yourself around every vaccine. [R11]

Report recurrent or unusually severe infections and any treatment interruptions they cause. They may change the safety assessment even when autoimmune symptoms improve.

Fever or substantial deterioration while taking immune-suppressing treatment needs timely clinical assessment, not a wait for the next routine blood test. The symptoms and overall condition determine urgency. Severe acute illness needs care even after a recent normal blood count.

Back to contents ↑

What other long-term health checks belong in the plan?

Usual preventive care remains important. Blood pressure, cardiovascular risk, bone health, falls and age-appropriate screening do not disappear because Sjögren’s has become the main diagnosis.

Long courses of systemic glucocorticoids, often called steroids, can increase fracture risk. Discuss bone assessment and prevention when prolonged treatment is planned, without waiting for a fracture. Tests and preventive treatment depend on overall risk; taking a steroid does not mean everyone needs the same osteoporosis medicine. [R13]

Planning a pregnancy is another reason for an earlier review. Medicine safety in pregnancy, disease control and possible effects of anti-Ro/SSA antibodies on the baby are separate questions that need a coordinated plan. The EULAR reproductive guideline cited here addresses medicines; it does not cover every aspect of monitoring the baby. [R14]

New features suggesting an overlapping condition also deserve reassessment. Anticentromere antibodies alone do not mean that every systemic-sclerosis test must be repeated on the same schedule as in established scleroderma. The actual clinical pattern matters. Keep primary care and the relevant specialists involved so each responsibility is clear. [R15]

Back to contents ↑

Does “stable” mean treatment should stay the same forever?

No. Continuing, reducing or changing treatment should be a deliberate decision based on benefit, disease risk and treatment burden. Stability can be an important success, but it is not a reason to stop reviewing the plan.

A medicine may prevent deterioration without producing a fresh improvement every day. Conversely, ongoing side effects or objective worsening can justify reconsideration. Persistent pain or fatigue may need its own treatment even if immune disease is controlled. A familiar antibody result or one normal inflammation marker cannot decide this alone. [R01] [R02]

After a change, agree what will be assessed and when, including side effects. When treatment is reduced, clarify which changes should prompt earlier contact. If it stays the same, understand what it is protecting or improving.

That makes continuing treatment an explained decision. It also separates an agreed reduction from an unrecorded interruption caused by intolerance, cost or misunderstanding. The treatment-response chapter explains these situations further.

Back to contents ↑

Which changes should not wait until my scheduled visit?

A new severe or rapidly changing problem takes priority over the usual schedule. Do not automatically assume it is another Sjögren’s symptom.

Seek emergency care now for severe breathlessness at rest, chest pain with acute illness, collapse, sudden weakness or speech difficulty, severe confusion, or major sudden loss of vision. Marked weakness with palpitations or a known serious electrolyte disturbance may also need emergency assessment.

Seek same-day assessment for a hot swollen joint with fever, a painful swollen gland with fever, new rapidly worsening weakness, or substantial illness while taking immune-suppressing treatment.

New eye pain with light sensitivity or reduced vision needs urgent eye assessment. If the change is sudden or severe, get help immediately. [R01] [R05] [R16] [R17]

Arrange prompt direct assessment for persistent gland or lymph-node swelling, unexplained weight loss, drenching night sweats, progressive breathlessness or concerning new kidney findings. Do not wait months for the routine appointment. These changes do not always mean a dangerous complication, but their cause needs to be established.

An educational website and nonurgent message channels are not emergency services.

Back to contents ↑

What should my personal follow-up plan contain?

A useful plan makes the next action clear. It can be brief, but it should identify what is being followed and who will review the results.

Write downA useful question
Current targetWhich symptom, organ or treatment risk are we following?
ComparisonWhich dated result or everyday ability is the baseline?
Next stepWhich test or appointment is needed, and why?
Timing and responsibilityWhen is it due, and who reviews it?
Earlier triggerWhich change should prompt contact before that date?
Result pathwayHow will I receive the interpretation and next decision?

This is an original planning aid, not a validated score or a diagnostic test. Use a separate line for each issue when the dates differ. If a result has not arrived, check whether the responsible team received it; silence does not prove that someone reviewed it.

Keep the plan with your medication list and important reports. Its purpose is to make care easier to follow, avoid missed steps and reduce unnecessary duplicate tests. You do not need constant testing or a life centered on monitoring the illness.

Back to contents ↑

Sources

  1. [R01] BSR adult and juvenile Sjögren disease guideline (2024/2025)
  2. [R02] EULAR topical and systemic Sjögren’s treatment recommendations · https://pure-oai.bham.ac.uk/ws/files/77434875/EULAR_Sjogren_tx_guidelines_v2.pdf
  3. [R03] 2023 ACR/CHEST guideline for screening and monitoring of ILD in systemic autoimmune rheumatic diseases (2024)
  4. [R04] ERS/EULAR connective tissue disease-associated ILD guideline (first published online 2025; 2026 issue)
  5. [R05] Deboo et al. Peripheral nervous system manifestations in Sjögren’s: guideline (first published online 2025; 2026 issue)
  6. [R06] AAO screening for hydroxychloroquine retinopathy: 2025 revision (2026 issue)
  7. [R07] 2025 BSR guideline for prescription and monitoring of conventional synthetic DMARDs (2026 issue)
  8. [R08] Hüper et al. Lymphoma in Sjögren: repetitive screening ultrasound in asymptomatic patients (2024/2025)
  9. [R09] Baer et al. Ultrasound-guided biopsy of suspected salivary gland lymphoma in Sjögren syndrome (2021)
  10. [R10] Clinical practice guidelines for oral management of Sjögren disease: dental caries prevention (2016)
  11. [R11] 2022 ACR guideline for vaccinations in rheumatic and musculoskeletal diseases (2023) · https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt1c0ef84075c925cf/vaccinations-guideline-manuscript-2022.pdf
  12. [R12] 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections (2023 issue)
  13. [R13] 2022 ACR guideline for prevention and treatment of glucocorticoid-induced osteoporosis (2023)
  14. [R14] EULAR antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update (2025)
  15. [R15] BSR systemic-sclerosis guideline (2024)
  16. [R16] Evans et al. Tubulointerstitial nephritis in primary Sjögren syndrome: manifestations and response to treatment (2016)
  17. [R17] NHS. Eye pain. Reviewed October 21, 2025.

About this publication

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Longitudinal assessmentMedication safetySjögren disease